Cautious Hold Rating on Nektar Therapeutics Amid Promising Yet Uncertain Clinical Developments

William Blair analyst Andy Hsieh has reiterated their neutral stance on NKTR stock, giving a Hold rating on July 31.

Andy Hsieh has given his Hold rating due to a combination of factors surrounding Nektar Therapeutics’ recent clinical trial developments and future plans. The company has reported promising initial results from the Phase IIb REZOLVE-AD trial for rezpeg in atopic dermatitis, showing dose-dependent improvement in EASI scores. However, the full implications of these results will only become clearer with the upcoming data presentations and the initiation of Phase III trials.
Furthermore, while the Phase IIb trial results are encouraging, the complete data from the maintenance portion of the study and the Phase III trial initiation are not expected until 2026. This timeline introduces a level of uncertainty and risk, as the long-term efficacy and safety of rezpeg remain to be fully validated. As such, Andy Hsieh’s Hold rating reflects a cautious approach, balancing the potential of the drug with the inherent risks and uncertainties in the clinical development process.

In another report released on July 31, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $22.00 price target.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NKTR in relation to earlier this year.